Research Peptide Comparisons
Each comparison puts two research compounds side by side in a single table: sequence and length, CAS number, molecular weight, receptor target, half-life, and how much published evidence stands behind each one. Where the literature is thin or absent for a compound, the table says so rather than implying equivalence. All compounds are described for in-vitro laboratory research use only.
Tesamorelin vs CJC-1295 (No DAC)
Tesamorelin vs CJC-1295 (No DAC): 44-residue GHRH analog with phase 3 human data versus a 29-residue fragment with none. CAS, formula, half-life, evidence gaps.
Ipamorelin vs Tesamorelin
Ipamorelin vs Tesamorelin: a 711.9 Da GHSR-1a pentapeptide against a 5,136 Da GHRH analog. Receptor targets, CAS, formula, and the trial-evidence gap between them.
Retatrutide vs Semaglutide
Retatrutide vs Semaglutide: triple GLP-1/GIP/glucagon agonism against single GLP-1 agonism. CAS, molecular weight, half-life, trial stage. Semaglutide is not stocked.
BPC-157 vs TB-500
BPC-157 vs TB-500: a 1,419.5 Da gastric pentadecapeptide against synthetic Thymosin β-4. Mechanisms, CAS, formula, the TB-500 naming ambiguity, and what the evidence does not show.
CJC-1295 (No DAC) vs Ipamorelin
CJC-1295 (No DAC) vs Ipamorelin: GHRH-receptor analog versus GHSR-1a agonist. Why they are blended rather than substituted, plus CAS, formula, mass and evidence limits.
KLOW Blend vs GLOW Blend
KLOW vs GLOW peptide blends: KLOW adds KPV to GLOW's GHK-Cu, BPC-157 and TB-500. Verified component identities, CAS numbers, masses, and what has never been tested.
Retatrutide vs Tirzepatide
Retatrutide vs Tirzepatide: triple GLP-1/GIP/glucagon agonism against dual GLP-1/GIP. The glucagon arm, CAS and mass data, half-lives, and the phase 2 versus phase 3 evidence gap.
Ipamorelin vs Sermorelin
Ipamorelin vs Sermorelin compared: GHSR-1a ghrelin-receptor agonist versus GHRH-receptor analog. Sequence, half-life. ≥99% purity, CoA. Research use only.